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Creationism and Evolutionism in Prions
Pierluigi GambettiFrom the Department of Pathology, Case Western Reserve University, Cleveland, OhioPrion diseases, earlier referred to as transmissible spongiform
encephalopathies, are rare conditions that have nonetheless
drawn considerable attention because they are transmissible,
affect both humans and animals, and are remarkably
heterogeneous in their phenotypic and molecular features.
The transmissibility to several mammalian species makes
prion diseases hazardous to public health, owing to their
propensity to spread not only between humans but also from
animals to humans. Transmissibility uniquely confers on
prion diseases three etiologies: sporadic, genetically deter-
mined, and acquired by infection.
Given these challenging features, it is not surprising that
the pathogenesis of prion diseases has been controversial. The
prion hypothesis, formally proposed by Stanley Prusiner in
1982, posits that the agent that causes the disease andmakes it
transmissible consists mostly, if not exclusively, of a protein
that he named proteinaceous infectious particle or prion.1 The
prion, now also identiﬁed as scrapie prion protein (PrPSc), is
derived from a normal protein well represented in mammals
(cellular prion protein, or PrPC) through a conformational
transition whereby PrPSc interacts with and templates PrPC,
forcing it to adopt the PrPSc abnormal conformation. Initially,
the prion hypothesis was intensely criticized by the propo-
nents of the viral etiology, but it has since been deﬁnitively
conﬁrmed; a series of experiments has demonstrated that
a typical prion disease can be engendered in wild-type
animals after inoculation of PrPSc generated in vitro from
recombinant PrP.2e5Supported by the NIH (NIA grant AG14359).
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It has been known for several decades that prions are formed
in distinct kinds, called strains, that can be experimentally
distinguished by the length of the incubation time and the
pattern of the brain lesions caused in the host after trans-
mission.6 Recently, prion strains have revealedmore complex
and dynamic features.6e8 Strain variation is commonlyCopyright ª 2013 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajpath.2012.12.016related to differences in the amino acid sequence between the
exogenous PrPSc and the PrPC of the host; such variation is
commonly found in transmission between species, but can
also occurwithin the same specieswhen PrPC heterogeneity is
due to polymorphism in the PrP gene.9 Even more revealing
mechanisms of strain diversity play out when PrPSc and PrPC
share amino acid sequence and the strain diversity is attrib-
utable merely to conformational differences.10
Prion strains are currently viewed as combinations or
ensembles of substrains (ie, a constellation of different kinds
of PrPSc characterized by distinct conformations and,
possibly, other physicochemical attributes), one of which is
dominant and imparts its characteristics to the strain as
a whole.7 When on inoculation such a strain cannot readily
template the host’s PrPC (owing to mismatch in amino acid
sequence, or to only limited conformational compatibility), it
must undergo a process of adaptation for the PrPC-to-PrPSc
conversion to occur and become more efﬁcient.6e8 This
adaptation generally requires two or more serial trans-
missions through the hosts, resulting in different outcomes,
depending on the degree of heterogeneity between the
exogenous PrPSc and the host PrPC. The presence in the strain
of substrain components capable of templating the host PrPC
may promote the emergence of a new dominant substrain. If
none of the substrains is compatible with the host’s PrPC, the
strain may change drastically, or mutate, resulting in a new
strain. The process of strain formation and selection becomes
fairly stereotyped after serial passages in syngeneic hosts as
the strain reaches the optimal combination of substrain
components to cause disease. This selection is commonly
revealed by the progressive reduction of the incubation time
required to reach the steady state.
GambettiSynthetic Strains
In 2004, Prusiner and colleagues2 published the ﬁrst evidence
that infectious mammalian prions could be generated in vitro
by refolding recombinant PrP into amyloid conformations.
An article by Ghaemmaghami et al11 in this issue of The
American Journal of Pathology reports the latest study from
the Prusiner research group, building on earlier research into
the design and construction of synthetic prion strains.12 The
study focuses on the process of synthetic strain adaptation
after multiple serial transmissions to mice. Using in vitro
manipulations, Ghaemmaghami et al11 generated four syn-
thetic prion preparations with amyloid-like characteristics by
inducing refolding of puriﬁed recombinant mouse PrP. The
four preparations (identiﬁed as MoSP5, MoSP6, MoSP7, and
MoSP9) were obtained with different procedures, and display
distinct ultrastructural and conformational stability features,
and can therefore be viewed as distinct prion strains.
After the ﬁrst inoculation or passage (P1) to transgenic mice
expressing four to eight times the normal amount of full-length
mouse PrPC, each preparation caused a prion disease after
average incubation times ranging from 500 to nearly 800 days,
which is quite lengthy incubation, compared with the 50-day
incubation required of the native prion strain RML (Figure 1).12
Six PrPSc strains were recovered at P1 from the transgenic mice
inoculated with the four MoSPs; these strains could be distin-
guished on the basis of PrPSc electrophoretic banding patterns,
incubation time, conformational stability, and amyloid seeding
capacity. The banding patterns observed were similar to thoseSynthetic strain MoSP5 MoSP6 MoSP7
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624described inhumanPrPSc andwerealso similarly identiﬁed.13,14
As for human PrPSc, types 1 and 2 were deﬁned by electro-
phoretic mobility at 21 or 19 kDa, respectively, of the ungly-
cosylated (or lowest) bandof PrPSc after protease treatment.13,14
At P1, Ghaemmaghami et al11 recovered PrPSc type 2 in
MoSP5, MoSP6, and MoSP7a, type 1 in MoSP7b, and type
1/2 (a mixture of the two types) in MoSP7c and MoSP9. Of
note, MoSP7 generated all three banding patterns (Figure 1).
After P1, the strains took seemingly unpredictable paths
through the various passages, generating intermediate forms
that often differed in the type of banding pattern, incubation
time, and stability. Interestingly, in MoSP7b, the banding
pattern that was type 1 at P1 switched to and remained type
2 through two more passages, and then reverted to type 1 at
P4; although both MoSP7c and MoSP9 were type 1/2 at P1,
only MoSP7c split into types 1 and 2. Nonetheless, all of the
P1 prion strains eventually converged into an apparently
common strain that was type 1, exhibiting similar low
conformational stabilities and amyloid seeding activities
(although some differences remained for incubation time).
On the basis of these ﬁndings, the authors conclude that
prion adaptation is not a straight process.11 Rather, it
appears to rely on a trial-and-error strategy, in which errors
are progressively corrected by Darwinian selection until the
most pathogenic strain is ultimately selected.6 The study by
Ghaemmaghami et al11 suggests additional considerations
concerning prion strain formation and evolution.
It should be emphasized that the various pathways leading
to the selection of the optimal strain were individuallyMoSP9
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Figure 1 In-pathway intermediate states and
ﬁnal forms of the four synthetic prion strains,
along with changes in incubation time, banding
pattern, and conformational stabilities after serial
passages in transgenic mice. MoSP7 generated all
three strain types (indicated as a, b, and c), which
traversed different intermediate states before
reaching the optimal condition. Strain MoSP7c
split into two distinct strains (1 and 2) at the
second passage. Strain characteristics in the
adapted state are highlighted in red. Data are
summarized from Figure 4 of Ghaemmaghami
et al.11
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Commentaryreproduced in sets of the same transgenic mice, with data
showing relatively narrow ranges (see Figure 4 of Ghaem-
maghami et al11). Furthermore, the selection process could be
replicated in cells, at least for one synthetic strain. Thus, the
selection pathways of the individual strains, although quite
different, were reproducible (and therefore not random),
presumably reﬂecting the presence of consistent constraints
in what the authors call a conformational landscape.11
It is widely accepted that the length of incubation time
(which reﬂects the pathogenicity) and conformational
stability are directly related. This relationship is expected,
given that unstable strains are more likely to fragment,
which makes the interaction with the PrPC substrate more
efﬁcient. On the whole, this observation is conﬁrmed by the
study of Ghaemmaghami et al.11 However, as the authors
also point out, these two characteristics became inversely
related in some of the passages (Figure 1). For example, in
the P2 conversion, in which PrPSc type 1 of MoSP7b and
type 1/2 of MoSP7c are each converted to PrPSc type 2, the
incubation time was drastically reduced but the stability
actually increased, compared with P1. This ﬁnding suggests
that pathogenicity and stability may be uncoupled under
certain conditions. In both MoSP7b and MoSP7c, the newly
formed and more stable PrPSc was type 2, but it remains to
be determined whether this result was coincidental or indi-
cates that the uncoupling of pathogenicity and stability is
a characteristic of the mouse PrPSc type 2 strain.
The study by Ghaemmaghami et al11 also leaves a few
issues to be addressed in future research. For instance, it
would be interesting to extend the characterization of the
strains to include the amount of total PrPSc and the size
distribution of the PrPSc aggregates. These additional data,
combined with those already collected, would provide
a more complete picture of the physicochemical character-
istics that the strain adopts while evolving toward the ﬁnal
isoform. These data would also expand the correlation of the
incubation time and stability to include the size of the
aggregates and the role, if any, played by the amount of
PrPSc in determining the increasing pathogenicity through
the serial passages. Infectivity has been shown to correlate
with aggregate size,15 and so prion evolution might include
shifts in aggregate size. Finally, it is surprising that no
apparent variation was detected in the type, topography, or
severity of the brain pathology throughout the various
passages, despite signiﬁcant variations in the banding
pattern, stability, or both. Perhaps detailed analysis of lesion
topography and severity may settle this issue.
Adaptation of synthetic prions through serial passages
has also been examined in hamsters by Baskakov and
colleagues.3 Although they did not study their panel of
synthetic prions in passages that are parallel to or easy to
compare with those of Ghaemmaghami et al,11 interesting
differences emerge between the two sets of studies. The
synthetic prions developed by Ghaemmaghami et al11
seemingly displayed fairly conventional banding patterns
even at P1 and evolved into stabilized strains with incubationThe American Journal of Pathology - ajp.amjpathol.orgtimes similar to those of native adapted strains. However,
Baskakov and colleagues3 observed atypical banding
patterns at early passages, and the incubation times remained
extended even after strain stabilization; furthermore, in their
experiments, animals were asymptomatic at P1. Because,
after careful search, no authentic PrPSc component was
detected in their synthetic prion preparation, Baskakov and
colleagues3 attributed the lack of clinical disease at P1 and
the gradual appearance of typical PrPSc to the strong con-
formational barrier (ie, the conformational constraints
encountered by the synthetic strain in templating the host
PrPC). At variance with the study of Ghaemmaghami et al,11
Baskakov and colleagues exposed their hamster recombinant
PrP amyloid ﬁbers to heat (ie, annealing). Furthermore, they
used wild-type animals, not animals overexpressing PrPC.
These methodological differences might explain the variation
in the adaptation process between the sets of strains devel-
oped by the two research groups.Native Human Strains
How applicable are the data of Ghaemmaghami et al11 (as
well as other current notions on strains) to human prion
diseases and to other neurodegenerative conditions? Of the
three etiological forms of human prion diseases (ie,
sporadic, inherited, and acquired by infection), current data
on prion strains most readily apply to the form acquired by
infection, especially to the best-known infection, variant
CreutzfeldteJakob disease (vCJD), which is acquired from
the consumption of meat or byproducts from prion-
contaminated cattle. However, nearly 90% of human prion
diseases are sporadic (Table 1), and the nature and selection
process of the prion strains associated with the sporadic
form are poorly deﬁned, in part because the mode of
formation of PrPSc in the sporadic form remains enigmatic,
owing to the lack (at least until very recently) of robust
experimental models of sporadic prion disease.16
Human sporadic prion diseases comprise three types (CJD,
fatal familial insomnia, and variably protease sensitive
prionopathy), and include ﬁve well-deﬁned subtypes of
sporadic CJD (sCJD) (Table 1). The ﬁve sCJD subtypes are
consistently associated with distinct clinical and histopatho-
logical phenotypes, which are thought to be determined by
the pairing of the PrP genotype at codon 129 and the features
of the associated strain.10,17 Human codon 129 is the site of
a common methionine/valine (M/V) polymorphism that
exchanges the amino acid sequence of the PrPC encoded by
each PrP allele, thereby generating three PrPC isoforms:
129MM, 129MV, and 129VV. The major strain character-
istic codistributing with the phenotype is the banding pattern
that distinguishes the PrPSc in types 1 and 2 in precisely the
way described by Ghaemmaghami et al.11 Altogether, at least
ﬁve distinct strains are thought to be associated with sCJD.10
Strain formation and selection in sporadic prion diseases
poses several new challenges. Most intriguing are the625
Table 1 Classiﬁcation of Human Prion Diseases
Phenotype, by form or etiology
Sporadic
Sporadic CreutzfeldteJakob disease (sCJD)
sCJDMM(MV)1*
sCJDMM2
sCJDVV1
sCJDVV2
sCJDMV2
Fatal insomnia
Variably protease sensitive prionopathy (VPSPr)
Familial
Familial CreutzfeldteJakob disease (fCJD)
Fatal familial insomnia (FFI)
GerstmanneSträusslereScheinker disease (GSS)
Acquired by infection
Variant CJD
Kuru
Iatrogenic CJD
Forms, types, and subtypes have been simpliﬁed for clarity.
*The letters MM, MV, and VV refer to the genotype at codon 129 of the
prion protein gene; the numbers 1 and 2 refer to the PrPSc banding pattern
or type.
Gambettimechanisms of the initial PrPC-to-PrPSc conversion. Com-
pelling evidence points to the failure (likely to be age-related)
of the quality-control complex known as the proteostasis
network to clear misfolded PrPSc-like species that are
produced under normal cellular conditions as a result of
intrinsic errors in protein biosynthesis.17 The initial PrPSc
would be formed in a limited region of the brain, or even in
a single cell; from the site of formation, the PrPSc would
then propagate to other brain regions, where it would cause
tissue damage.10
Little is known about strain formation when PrPSc, as
described above, is formed de novo in the absence of an
exogenous strain to template the PrPC. It is unclear whether
the initial conversions generate substrains that then undergo
a selection process culminating in the rise of a dominant
isoform, as happens after inoculation of an exogenous
strain, or whether these events happen before or during
propagation.
De novo prion strain formation and evolution must also
accommodate the repetitiveness of the individual sporadic
phenotypes and, thus, of their associated strains. The con-
sistency of individual strains indicates that the de novo PrPSc
isoforms follow a relatively limited number of formation and
evolution pathways. This view is fully consistent with the
ﬁndings of Ghaemmaghami et al.11
The sCJD subtypes are often associated with both PrPSc
types 1 and 2 (what Ghaemmaghami et al11 call type 1/2). Each
strain type appears to be fully mature and competent to
determine its own speciﬁc phenotype, a condition that leads to
the formation of phenotypes with hybrid characteristics.
Furthermore, when the two strain types coexist in the same
brain region, they reciprocally affect some of their character-
istics (eg, their conformational stability). The co-occurrence of626the two strain types raises the question of whether one results
from the mutation of the other or whether they are formed de
novo concurrently.
Finally, if strains determine the phenotype, then they
must not form randomly in sCJD, because the prevalences
of the CJD phenotypes are markedly different. Although
sCJDMM(MV)1 accounts for approximately 60% of spo-
radic cases, sCJDVV1 is observed in only approximately
2% of cases; other subtypes have intermediate preva-
lences.17 Whether this lopsided strain occurrence is estab-
lished at the time of the initial formation of PrPSc or whether
it represents different selection patterns is currently unknown.
Ghaemmaghami et al11 observed co-occurrence of types 1
and 2 at P1, but the two types were segregated in subse-
quent passages (Figure 1). Studies now in progress with
serial passages of the human 1/2 PrPSc to human PrPC-
expressing transgenic mice may show whether a similar
outcome also applies to human prion 1/2 co-occurrence
(I. Cali and Q. Kong, personal communication). This kind
of experiment may also help clarify whether PrPSc species
associated with sCJD are authentic strains or represent
intermediate states.
It has recently been observed that the prion principle (ie,
the recruitment of a normal protein into a conformationally
pathogenic isoform) also applies to several other neurode-
generative diseases.18 In fact, Alzheimer disease and tau
proteinerelated diseases (or some of the basic histopatho-
logical features of these diseases) have been transmitted to
receptive hosts. Similar ﬁndings, albeit preliminary, have
also been obtained in other neurodegenerative diseases,
including Parkinson disease and amyotrophic lateral scle-
rosis. Strain presence is one of the issues raised by these
ﬁndings.10 More than 10 years ago, it was reported that
familial forms of Alzheimer disease with distinct disease
phenotypes are associated with distinct electrophoretic
banding patterns of amyloid b, the primary pathogenic
peptide in Alzheimer disease.19 Pathogenic presenilin-1
mutations, which give rise to a malignant phenotype, were
associated with signiﬁcantly more amyloid b fragments
truncated at the N-terminus than full-length amyloid b; the
opposite ratio was observed in other mutations with typical
phenotypes and in sporadic Alzheimer disease. This ﬁnding
suggests that the cleavage of amyloid b at different sites,
which generates distinct banding patterns, is associated with
distinct phenotypes, a scenario similar to that leading to the
formation of PrPSc types 1 and 2 in prion diseases. There-
fore, it would not be surprising if strains are shown to exist
and play a role in Alzheimer disease and other nonprion
neurodegenerative diseases.
The use of human synthetic strains in experiments such as
those conducted by Ghaemmaghami et al11 may help clarify
some of these issues. In addition, animal models of spon-
taneous human prion disease and cells capable of propa-
gating human prion strains must be developed, and the
application of prion technologies to other neurodegenerative
diseases must be aggressively pursued.ajp.amjpathol.org - The American Journal of Pathology
CommentaryConclusions
The study by Ghaemmaghami et al11 focuses on the evolu-
tionary process that prions undergo after serial passages in
syngeneic hosts to reach a conformer that is stable and most
pathogenic and that fulﬁlls the characteristics of the fully
adapted prion strain. A major merit of their study is the use of
several synthetic prion preparations that are purposely
heterogeneous but are all capable of causing a prion disease
in the same host. Theoretically, synthetic prions are powerful
tools to dissect conformational and other features that are
related to banding pattern, infectivity and pathogenicity. For
example, at P1, Ghaemmaghami et al11 generated each of the
three PrPSc banding patterns that seemingly are similar to
those observed in sCJD. Detailed conformational analyses of
the synthetic prion developed in their study (and of future,
more efﬁcient ones) may reveal the features that lead to
evolution into PrPSc type 1, type 2, or both types at the same
time. More importantly, such analyses may reveal the
conditions that make a prion highly pathogenic or harmless,
and whether these conditions have therapeutic applications.
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